Takeda Lays Out Teva JV Impact, Confirms Blopress Transfer

Takeda has identified its first mature products to be transferred next April to a new joint venture with Teva, in a transaction it expects to be cash flow accretive next fiscal year despite an initial hit on revenues and operating profit.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia